View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 20, 2021updated 02 Dec 2021 6:20am

CanSino Biologics to start clinical trials of inhaled Covid-19 vaccine 

Chinese company CanSino Biologics is set to commence clinical trials of a Covid-19 vaccine that can be administered through inhalation.

Chinese company CanSino Biologics is set to commence clinical trials of a Covid-19 vaccine that can be administered through inhalation.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

CNBC reported that, in collaboration with the Beijing Institute of Biotechnology (BIB), CanSinoBIO is developing the inhalation vaccine.

The news channel quoted CanSino Biologics co-founder and chief executive Xuefeng Yu as saying that an inhaled vaccine could be more effective compared to injected ones as SARS-COV-2 enters the human body through the airways.

Yu added that, theoretically, an inhaled vaccine can activate antibodies or T cells in the airways and offer extra protection. In the event of protection layer failure and the entry of the virus deep into the body, other parts of the immune system could still work against the virus.

The inhaled vaccine is based on the same technology used by the company while researching an inhaled tuberculosis vaccine and its injectable Covid-19 vaccine.

The company’s injectable Adenovirus Type 5 Vector vaccine (Ad5-nCoV) is already approved for use in China and many other countries.

According to interim data from Phase III clinical trials outside the country, the vaccine demonstrated 68.83% effectiveness in preventing symptomatic Covid-19 two weeks after one injection with the rate falling to 65.28% after four weeks, reported Reuters.

Chinese regulators had granted permission to conduct the first trial of a nasal spray vaccine developed by scientists at Hong Kong University (HKU), Xiamen University (XMUM), and Beijing Wantai Biological Pharmacy Enterprise last September.

In January, Indian drug regulator CDSCO’s subject expert committee recommended granting permission for conducting Phase I clinical trial of Bharat Biotech’s intranasal Covid-19 vaccine (BBV154).

In March, Hong Kong University concluded the Phase I/II trial of the vaccine in China and is currently enrolling participants for a second Phase I trial in Hong Kong, China.

During the same period, the University of Oxford announced the launch of a study analysing the delivery of the ChAdOx1 nCoV-19 coronavirus vaccine using a nasal spray. It is based on the Covid-19 vaccine developed in collaboration with AstraZeneca.

Recently, the efficacy rates of Chinese Covid-19 vaccines were found to be lesser than vaccines of Pfizer-BioNTech and Moderna.

The Chinese Center for Disease Control director had noted that the Chinese vaccines do not have great protection rates and they intend to administer people with different shots to increase the efficacy of the vaccines.

Separately, Chinese researchers are conducting a trial by mixing Covid-19 vaccines developed by CanSinoBIO and a unit of Chongqing Zhifei Biological Products, the news agency reported. This trial, which is progressing in the eastern city of Nanjing, will enrol 120 subjects.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU